- Planning for the April 2010 ARRA recipient reporting period and wondering what to do about non-competing continuation (Type 5) awards?
- Beginning to close out ARRA supplements?
- Wondering whether a second no-cost extension is an option for an ARRA grant?
Three new Guide Notices were recently published that can provide valuable tips and clarifications.
Notice NOT-OD-10-065 addresses a number of quarterly recipient reporting issues. These include clarifications on reporting award numbers and award amounts for ARRA non-competing continuation (Type 5) awards, guidance for reporting on relinquished ARRA grants, and reminders of common submission errors identified in previous reporting quarters.
On a related note, we have received questions about when grantees can file their final quarterly recipient reports at FederalReporting.gov. To clear up any confusion, a final ARRA quarterly report should be submitted if the project is complete (Project Status=Fully Completed) and all reported funds expended on the project are consistent with the final expenditures to be reported in the NIH closeout documents (i.e., final Financial Status Report). We incorrectly stated last month that until all closeout documents are received by NIH, you need to continue reporting to FederalReporting.gov. Instead, separate closeout documents may be submitted to NIH after the final quarterly report is submitted to FederalReporting.gov.
Notice NOT-OD-10-066 reminds grantees of NIH-specific reporting requirements. Although NIH has updated its systems to handle the closeout of a single supplement or revision separate from the parent grant, the system is not able to accommodate separate financial reporting. So in these situations, you are only required to submit a single Financial Status Report at the time the project period of the last ARRA supplement or revision ends.
Notice NOT-OD-10-067 reminds you of the importance of working expeditiously to employ scientific staff to meet the Recovery Act’s goals of stimulating economic development activity and increasing the tempo of scientific research. Unexpected delays should be addressed promptly, and second no-cost extensions will be strictly limited.
0 Comments